Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial

K Dinkelborg, J Kahlhöfer, P Dörge, C Yurdaydin, S Hardtke, F A Caruntu, M G Curescu, K Yalcin, U S Akarca, S Gürel, S Zeuzem, A Erhardt, S Lüth, G V Papatheodoridis, O Keskin, K Port, M Radu, M K Celen, R Idilman, K Weber, J Stift, U Wittkop, B Heidrich, I Mederacke, H von der Leyen, H P Dienes, M Cornberg, A Koch, M P Manns, H Wedemeyer, K Deterding